Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand

Current HIV Research

Volumn 9, Issue 5, 2011, Pages 334-338

  Chaiwarith, Romanee ^a   Fakthongyoo, Apinya ^a   Praparattanapan, Jutarat ^a   Boonmee, Darakorn ^a   Sirisanthana, Thira ^b   Supparatpinyo, Khuanchai ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b Research Institute for Health Sciences   (Thailand)

Author keywords

Fluconazole; Fungal infections; HIV infection; Itraconazole; Primary prophylaxis

Indexed keywords

EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC MYCOSIS; THAILAND;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FLUCONAZOLE; HUMANS; INCIDENCE; ITRACONAZOLE; MALE; MYCOSES; RETROSPECTIVE STUDIES; THAILAND;

EID: 80053949888     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211797635991     Document Type: Article

References (22)

1. AIDS situation in Thailand. Available from http://www.boe.moph. go.th/report.php?cat=68 [Cited 2011 February 12].
2. Asselman V, Thienemann F, Pepper DJ, et al. Central nervous system disorders after starting antiretroviral therapy in South Africa. AIDS 2010; 24: 2871-6.
3. Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996; 23: 125-30.
4. Seboxa T, Alemu S, Assefa A, Asefa A, Diro E. Cryptococcal meningitis in patients with acquired immunudeficiency syndrome in prehaart era at Gondar College of Medical Sciences Hospital north-west Ethiopia. Ethiop Med J 2010; 48: 237-41.
5. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344: 110-3.
6. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Available from http: //www.aidsinfo.nih.gov/guidelines [Cited 2011 Feb 11].
7. 2000-2001 IDTHAI HIV Treatment Guideline. Available from http: //www.idthai.org/HIV/HIV_guidelines.htm [Cited 2011 February 12].
8. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992; 6: 191-4.
9. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332: 700-5.
10. Singh N, Barnish MJ, Berman S, et al. Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial. Clin Infect Dis 1996; 23: 1282-6.
11. Havlir DV, Dube MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998; 27: 1369-75.
12. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34: 277-84.
13. McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28: 1049-56.
14. Anekthananon T, Ratanasuwan W, Techasathit W, Rongrungruang Y, Suwanagool S. HIV infection/acquired immunodeficiency syndrome at Siriraj Hospital, 2002: time for secondary prevention. J Med Assoc Thai 2004; 87: 173-9.
15. McLeod DS, Mortimer RH, Perry-Keene DA, et al. Histoplasmosis in Australia: report of 16 cases and literature review. Medicine (Baltimore) 2011; 90: 61-8.
16. Wang TL, Cheah JS, Holmberg K. Case report and review of disseminated histoplasmosis in South-East Asia: clinical and epidemiological implications. Trop Med Int Health 1996; 1: 35-42.
17. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321: 794-9.
18. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000; 14: 1401-7.
19. Wu TC, Chan JW, Ng CK, Tsang DN, Lee MP, Li PC. Clinical presentations and outcomes of Penicillium marneffei infections: a series from 1994 to 2004. Hong Kong Med J 2008; 14: 103-9.
20. Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, Suebsaeng L, Lo YR. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand. Southeast Asian J Trop Med Public Health 2006; 37: 704-15.
21. Ungass Country Progress Report Thailand. Reporting period January 2008 - December 2009. http: //www.unaids.org/en/ Regionscountries/Countries/Thailand/ [Cited 2011 February 13].
22. Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993; 37:2407-11.